Clinical Trial Update: A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study evaluating SKB264 in combination with pembrolizumab versus chemotherapy with pembrolizumab as first-line tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• SKB264

Snippet

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING